Format

Send to

Choose Destination
Clin Exp Rheumatol. 2018 Mar-Apr;36(2):215-222. Epub 2017 Oct 23.

Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).

Author information

1
University of Western Ontario, London; Saint Joseph's Health Care, London, ON, Canada. janet.pope@sjhc.london.on.ca.
2
JSS Medical Research, St-Laurent, QC, Canada.
3
JSS Medical Research, St-Laurent, QC; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
4
Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
5
JSS Medical Research, St-Laurent, QC; McGill University, Montreal, QC, Canada.
6
Toronto General Hospital Research Institute, University Health Network, Toronto; Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto; Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.

Abstract

OBJECTIVES:

In active rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX), guidelines support adding or switching to another conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and/or a biologic DMARD (bDMARD). The purpose of this analysis was to describe treatment practices in routine care and to evaluate determinants of regimen selection after MTX discontinuation.

METHODS:

Biologic-naïve patients in the Ontario Best Practice Research Initiatives registry discontinuing MTX due to primary/secondary failure, adverse events, or patient/physician decision were included.

RESULTS:

Of 313 patients discontinuing MTX, 102 (32.6%) were on MTX monotherapy, 156 (49.8%) on double, and 55 (17.6%) on multiple csDMARDs. Patients on MTX monotherapy were older than patients on double or multiple csDMARDs (p=0.013), less likely to have joint erosions (p=0.009) and had lower patient global assessment (p=0.046) at MTX discontinuation. Post-MTX discontinuation, 169 (54.0%) transitioned to, or added new DMARD(s) (new csDMARD(s): 139 [44.4%]; bDMARD: 30 [9.6%]), and 144 (46.0%) opted for no new DMARD treatment. Patients on MTX monotherapy transitioning monotherapy, whereas patients on combination csDMARDs switched more to new csDMARDs and bDMARD combination therapy. Early RA (adjOR [95%CI]: 3.07 [1.40-6.72]) and treatment with multiple csDMARDs vs. MTX monotherapy (4.15 [1.35-12.8]) at MTX discontinuation were significant predictors of transitioning to or adding new csDMARD(s)/bDMARD treatment versus opting for no new DMARD treatment.

CONCLUSIONS:

Differences in subsequent treatment patterns exist between patients discontinuing MTX when used as monotherapy versus in combination with other csDMARDs where the former are more likely to use a subsequent monotherapy treatment.

PMID:
29148403
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Clinical and Experimental Rheumatology
Loading ...
Support Center